Joan T. Merrill mainly focuses on Internal medicine, Lupus erythematosus, Immunology, Placebo and Connective tissue disease. Her studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery. Joan T. Merrill has researched Lupus erythematosus in several fields, including Systemic lupus erythematosus, Randomized controlled trial, Human leukocyte antigen and Cohort.
Her Immunology study combines topics in areas such as Genotype, Single-nucleotide polymorphism and Haplotype. Her research in Placebo intersects with topics in Belimumab and Adverse effect, Pharmacology. Her Connective tissue disease research incorporates elements of Systemic disease, Immunopathology and Quality of life.
Joan T. Merrill mainly investigates Internal medicine, Immunology, Systemic lupus erythematosus, Lupus erythematosus and Rheumatology. The various areas that Joan T. Merrill examines in her Internal medicine study include Gastroenterology and Placebo. She regularly ties together related areas like Disease in her Immunology studies.
Her Systemic lupus erythematosus study deals with Cohort intersecting with Cohort study. Her research investigates the connection between Lupus erythematosus and topics such as Connective tissue disease that intersect with issues in Immunopathology. Her Rheumatology research is multidisciplinary, relying on both Quality of life, Systemic lupus, Physical therapy, Pediatrics and INCEPTION COHORT.
Her primary areas of study are Internal medicine, Systemic lupus erythematosus, Lupus erythematosus, Clinical trial and Placebo. In her research, Joan T. Merrill performs multidisciplinary study on Internal medicine and In patient. Joan T. Merrill interconnects Disease severity, Anti-nuclear antibody, Quality of life, Immune system and Abatacept in the investigation of issues within Systemic lupus erythematosus.
Her study in Lupus erythematosus is interdisciplinary in nature, drawing from both Young adult, Pregnancy, Physical therapy and Severity of illness. Her Placebo study also includes fields such as
Internal medicine, Lupus erythematosus, Systemic lupus erythematosus, Young adult and Clinical trial are her primary areas of study. Her Internal medicine study frequently draws connections to other fields, such as Placebo. Her studies deal with areas such as Odds ratio, Pregnancy, Predictive value of tests and Severity of illness as well as Lupus erythematosus.
In her research, Complex disease, Physical therapy and Systemic therapy is intimately related to Disease activity, which falls under the overarching field of Systemic lupus erythematosus. Her work deals with themes such as Polypharmacy, Intensive care medicine and Adverse effect, which intersect with Clinical trial. Her Transcriptome research includes themes of Plasma cell and Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon.
Arthritis & Rheumatism (2012)
Human polymorphism at microRNAs and microRNA target sites.
Liuqing Yang;Chunru Lin;Chunyu Jin;Joy C. Yang.
Frontiers in Genetics (2013)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill;C. Michael Neuwelt;Daniel J. Wallace;Joseph C. Shanahan.
Arthritis & Rheumatism (2010)
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Bevra H. Hahn;Maureen A. McMahon;Alan Wilkinson;W. Dean Wallace.
Arthritis Care and Research (2012)
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci.
John B. Harley;John B. Harley;John B. Harley;Marta E. Alarcón-Riquelme;Lindsey A. Criswell;Chaim O. Jacob.
Nature Genetics (2008)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera.
Arthritis & Rheumatism (2011)
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
Ellen M. Ginzler;Mary Anne Dooley;Cynthia Aranow;Mimi Y. Kim.
The New England Journal of Medicine (2005)
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial
Jill P. Buyon;Michelle A. Petri;Mimi Y. Kim;Kenneth C. Kalunian.
Annals of Internal Medicine (2005)
Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie;Munther Khamashta;Joan T. Merrill;Victoria P. Werth.
Arthritis & Rheumatism (2017)
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
Daniel J. Wallace;William Stohl;Richard A. Furie;Jeffrey R. Lisse.
Arthritis Care and Research (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: